Ab
ocrelizumab
vepalimomab
glembatumumab
atezolizumab
antinucleosome
agonistic monoclonal antibody
teplizumab
-mab
dorlixizumab
monoantibody
serospecific
soravtansine
sibrotuzumab
mapatumumab
bococizumab
carlumab
naptumomab estafenatox
anticorrelate
drozitumab
antidesmoglein
dalotuzumab
thrombophylactic
guselkumab
evolocumab
lexatumumab
adecatumumab
robatumumab
antiserum
siltuximab
autocentromere
ipilimumab
milatuzumab
antipolyvalent
immunoglobin
zanolimumab
pamrevlumab
antisubstance
teprotumumab
figitumumab
thrombocythemia
cergutuzumab
tucotuzumab
bavituximab
antiphosphospecific
elotuzumab
sonepcizumab
dacetuzumab
thrombosuppressive
seroblock